Posted by Michael Wonder on 12 Jun 2024
Voxelotor for the treatment of patients with haemolytic anaemia caused by sickle cell disease
12 June 2024 - NICE has published final evidence-based recommendations on the use of voxelotor (Oxbryta) for the treatment of patients with haemolytic anaemia caused by sickle cell disease.
Voxelotor, when used as monotherapy or in combination with hydroxycarbamide (hydroxyurea), is recommended for the treatment of patients 12 years and older with haemolytic anaemia caused by sickle cell disease only if are ineligible for, or intolerant of hydroxycarbamide, or hydroxycarbamide alone is insufficiently effective.
